These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2854864)

  • 1. [Fundamental studies, reference values, and clinical evaluation of abnormal prothrombin PIVKA-II assay using monoclonal antibody (E-1023)].
    Sakurabayashi I; Kawai T; Omizo R; Hattori N; Ishii M
    Rinsho Byori; 1988 Dec; 36(12):1407-12. PubMed ID: 2854864
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical evaluation of PIVKA-II in patients with hepatocellular carcinoma. Detection of PIVKA-II by EIA using anti-PIVKA-II monoclonal antibody].
    Ohtani M; Ido K; Kawamoto C; Kimura K
    Rinsho Byori; 1989 Apr; 37(4):405-9. PubMed ID: 2545953
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies.
    Nakao A; Taniguchi K; Inoue S; Takeda S; Harada A; Nonami T; Watanabe K; Takagi H
    Am J Gastroenterol; 1997 Jun; 92(6):1031-4. PubMed ID: 9177525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of plasma PIVKA-II as a new marker for hepatocellular carcinoma].
    Tada H; Kagawa K; Hikita H; Takeuchi T; Ohta Y; Fukui S; Shintani H; Deguchi T; Okanoue T; Takino T
    Gan No Rinsho; 1989 Apr; 35(5):564-70. PubMed ID: 2469809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A staining method of PIVKA-II by an indirect immunoenzyme technic].
    Tanimoto K; Onji M; Nadano S; Kumon I; Michitaka K; Horiike N; Ohta Y
    Rinsho Byori; 1989 Oct; 37(10):1139-42. PubMed ID: 2481050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical signification and evaluation of PIVKA-II in hepatocellular carcinoma].
    Matsushima A; Enomoto M; Yokoo Y; Arai M; Kobayashi T; Okuno F; Hirano Y; Sujita K; Eto S; Takagi T
    Rinsho Byori; 1989 Jun; 37(6):683-6. PubMed ID: 2477568
    [No Abstract]   [Full Text] [Related]  

  • 7. Performance characteristics of the LiBASys des-gamma-carboxy prothrombin assay.
    Owen WE; Roberts RF; Roberts WL
    Clin Chim Acta; 2008 Mar; 389(1-2):183-5. PubMed ID: 18164263
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical usefulness of serum PIVKA-II levels determined by ECLIA system as a tumor maker for hepatocellular carcinoma].
    Sakizono K; Oita T; Shibata Y; Tamura A; Kasakura S
    Rinsho Byori; 1998 Sep; 46(9):936-41. PubMed ID: 9800480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
    Lamerz R; Runge M; Stieber P; Meissner E
    Anticancer Res; 1999; 19(4A):2489-93. PubMed ID: 10470180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical significance of des-gamma-carboxy prothrombin assay as a tumor marker].
    Yamano M
    Nihon Rinsho; 1990 Feb; 48 Suppl():999-1002. PubMed ID: 1693989
    [No Abstract]   [Full Text] [Related]  

  • 11. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
    Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M
    Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of highly sensitive assay for detection of low serum level of PIVKA-II and its clinical usefulness].
    Sakizono K; Oita T; Kuroda M; Kasakura S
    Rinsho Byori; 1996 Sep; 44(9):871-6. PubMed ID: 8911073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma].
    Yamashiki M; Kosaka Y
    Rinsho Byori; 1989 Feb; 37(2):118-21. PubMed ID: 2471846
    [No Abstract]   [Full Text] [Related]  

  • 14. Abnormal prothrombin (PIVKA-II) and hepatocellular carcinoma.
    Okuda H; Nakanish T; Furukawa M; Yamagata H; Obata H
    Trop Gastroenterol; 1991; 12(2):59-66. PubMed ID: 1719681
    [No Abstract]   [Full Text] [Related]  

  • 15. Acarboxy prothrombin (PIVKA II) as a tumour marker for hepatocellular carcinoma and other liver diseases.
    Mohamedein A; Yousif-Kadaru AG; Ahmed SA; Saida H; Zaki ZA; Eldin ; Fedail SS
    East Afr Med J; 1995 Sep; 72(9):584-7. PubMed ID: 7498046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
    Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tumor markers of hepatocellular carcinoma].
    Kubo S; Matsukawa M
    Gan To Kagaku Ryoho; 2004 Dec; 31(13):2203-6. PubMed ID: 15628773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma.
    Nagaoka S; Yatsuhashi H; Hamada H; Yano K; Matsumoto T; Daikoku M; Arisawa K; Ishibashi H; Koga M; Sata M; Yano M
    Cancer; 2003 Dec; 98(12):2671-7. PubMed ID: 14669288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The des-gamma-carboxyprothrombin for the diagnosis of hepatocellular carcinoma.
    Brunello F; Marcarino C; Pasquero P; Gastaldi P; Gonella S; Martini S; Calcamuggi G; Emanuelli G
    Ital J Gastroenterol; 1993 Jan; 25(1):9-12. PubMed ID: 7679014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.